Yang Jing, Jiang Wenwen, Deng Jianqing, Liu Min, Xue Ya, Bao Jizhang, Jia Tingting, Hu Qi, Zhang Lichao
Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Med (Lausanne). 2025 Feb 25;12:1541235. doi: 10.3389/fmed.2025.1541235. eCollection 2025.
VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected with SARS-CoV-2. Based on clinical trials and pharmacokinetic analysis about VV116, we initiated a reduced dose of 300 mg every 12 h on day 1, 200 mg every 12 h on days 2-5 for antiviral therapy. Finally, the patient's viral load rapidly dropped to an undetected level, and no drug-related adverse effects were observed.
VV116是一种针对新型冠状病毒的口服抗病毒药物，以其良好的疗效和安全性而闻名。但其在严重肝功能不全患者中的应用尚未得到评估。在此，我们报告一例再生障碍性贫血合并肝损伤（急性肝衰竭恢复期）患者感染新型冠状病毒的病例。基于关于VV116的临床试验和药代动力学分析，我们在第1天开始每12小时给予300毫克的减量剂量，在第2至5天每12小时给予200毫克进行抗病毒治疗。最终，患者的病毒载量迅速降至检测不到的水平，且未观察到与药物相关的不良反应。
